表紙
市場調查報告書

個別·特殊荷爾蒙:醫療設備的開發平台評估

Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 666936
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
個別·特殊荷爾蒙:醫療設備的開發平台評估 Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月14日內容資訊: 英文 88 Pages
簡介

本報告提供全球個別·特殊荷爾蒙相關市場上的主要開發中產品及其臨床實驗進展調查,並彙整產品的功能·特性比較分析 (臨床實驗的各進展階段) ,及主要企業·組織的簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 個別·特殊荷爾蒙概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 個別·特殊荷爾蒙:臨床實驗中的開發中產品,各企業

  • 個別·特殊荷爾蒙的企業:各臨床實驗階段的開發中產品
  • 個別·特殊荷爾蒙:各臨床實驗階段的開發中產品

第5章 個別·特殊荷爾蒙市場:企業·產品概要

  • Alere Inc
  • AMS Diagnostics LLC
  • Beckman Coulter Inc
  • Carolina Liquid Chemistries Corp
  • Ceres Nanosciences Inc
  • Columbia University
  • DiaSorin SpA
  • DIAsource ImmunoAssays SA
  • Fujirebio Diagnostics Inc
  • Immunodiagnostic Systems Holdings plc
  • Mindray Medical International Ltd
  • Novartis AG
  • OJ-Bio Ltd
  • Roche Diagnostics International Ltd
  • Sendera Discovery
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc
  • Tosoh Bioscience Inc

第6章 個別·特殊荷爾蒙市場:目前的趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0821EPD

GlobalData's Medical Devices sector report, "Individual and Specified Hormones - Medical Devices Pipeline Assessment, 2019" provides an overview of Individual and Specified Hormones currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Individual and Specified Hormones pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Individual and Specified Hormones under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Individual and Specified Hormones and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Individual and Specified Hormones under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Individual and Specified Hormones Overview 7

3 Products under Development 8

  • 3.1 Individual and Specified Hormones - Pipeline Products by Stage of Development 8
  • 3.2 Individual and Specified Hormones - Pipeline Products by Segment 9
  • 3.3 Individual and Specified Hormones - Pipeline Products by Territory 10
  • 3.4 Individual and Specified Hormones - Pipeline Products by Regulatory Path 11
  • 3.5 Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 12

4 Individual and Specified Hormones - Pipeline Products under Development by Companies 13

  • 4.1 Individual and Specified Hormones Companies - Pipeline Products by Stage of Development 13
  • 4.2 Individual and Specified Hormones - Pipeline Products by Stage of Development 14

5 Individual and Specified Hormones Companies and Product Overview 16

  • 5.1 Alere Inc Company Overview 16
    • 5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.2 AMS Diagnostics LLC Company Overview 17
    • 5.2.1 AMS Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.3 Beckman Coulter Inc Company Overview 19
    • 5.3.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.4 Carolina Liquid Chemistries Corp Company Overview 20
    • 5.4.1 Carolina Liquid Chemistries Corp Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.5 Ceres Nanosciences Inc Company Overview 22
    • 5.5.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.6 Columbia University Company Overview 23
    • 5.6.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.7 DIANA Biotechnologies Company Overview 24
    • 5.7.1 DIANA Biotechnologies Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.8 DiaSorin SpA Company Overview 25
    • 5.8.1 DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.9 Immunodiagnostic Systems Holdings plc Company Overview 28
    • 5.9.1 Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.10 Novartis AG Company Overview 30
    • 5.10.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.11 OJ-Bio Ltd (Inactive) Company Overview 31
    • 5.11.1 OJ-Bio Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.12 Roche Diagnostics International Ltd Company Overview 32
    • 5.12.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.13 Sendera Discovery Company Overview 37
    • 5.13.1 Sendera Discovery Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.14 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 38
    • 5.14.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.15 Siemens Healthcare Diagnostics Inc Company Overview 44
    • 5.15.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.16 Siemens Healthineers AG Company Overview 51
    • 5.16.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.17 Tosoh Bioscience Inc Company Overview 52
    • 5.17.1 Tosoh Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 52

6 Individual and Specified Hormones- Recent Developments 53

  • 6.1 Nov 04, 2019: Luminex reports third quarter 2019 results and submission of VERIGENE II Gastrointestinal Flex Assay to the FDA 53
  • 6.2 Oct 16, 2019: Abbott reports third-quarter 2019 results 53
  • 6.3 Oct 01, 2019: Fortress Diagnostics announces £8m investment in new headquarters 56
  • 6.4 Sep 12, 2019: Repositioning of Biocrates: Management change and new round of financing 57
  • 6.5 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 57
  • 6.6 Jul 31, 2019: Luminex reports second quarter 2019 financial results and increase in quarterly dividend 58
  • 6.7 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 59
  • 6.8 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 60
  • 6.9 Jul 17, 2019: Abbott reports second-quarter 2019 results 61
  • 6.10 Jun 19, 2019: Immunodiagnostic Systems Holdings: Final results for year ended 31 March 2019 63

7 Appendix 85

  • 7.1 Methodology 85
  • 7.2 About GlobalData 88
  • 7.3 Contact Us 88
  • 7.4 Disclaimer 88

List of Tables

  • Table 1: Individual and Specified Hormones - Pipeline Products by Stage of Development 9
  • Table 2: Individual and Specified Hormones - Pipeline Products by Segment 10
  • Table 3: Individual and Specified Hormones - Pipeline Products by Territory 11
  • Table 4: Individual and Specified Hormones - Pipeline Products by Regulatory Path 12
  • Table 5: Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 13
  • Table 6: Individual and Specified Hormones Companies - Pipeline Products by Stage of Development 14
  • Table 7: Individual and Specified Hormones - Pipeline Products by Stage of Development 15
  • Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 9: Vitamin D Assay - Product Status 18
  • Table 10: Vitamin D Assay - Product Description 18
  • Table 11: AMS Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 12: LIASYS 330 - Vitamin D Assay - Product Status 19
  • Table 13: LIASYS 330 - Vitamin D Assay - Product Description 19
  • Table 14: Liasys 450 - Vitamin D Assay - Product Status 19
  • Table 15: Liasys 450 - Vitamin D Assay - Product Description 20
  • Table 16: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 17: UniCel DxI 860i Synchron Access Clinical System - Vitamin D Assay - Product Status 21
  • Table 18: UniCel DxI 860i Synchron Access Clinical System - Vitamin D Assay - Product Description 21
  • Table 19: Carolina Liquid Chemistries Corp Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 20: CLC 480 Analyzer - Vitamin D Assay - Product Status 22
  • Table 21: CLC 480 Analyzer - Vitamin D Assay - Product Description 22
  • Table 22: CLC 720i Analyzer - Vitamin D Assay - Product Status 24
  • Table 23: CLC 720i Analyzer - Vitamin D Assay - Product Description 24
  • Table 24: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 25: Nanotrap Human Growth Hormone Test - Product Status 25
  • Table 26: Nanotrap Human Growth Hormone Test - Product Description 25
  • Table 27: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 28: Diagnostic Test - Menopause - Product Status 26
  • Table 29: Diagnostic Test - Menopause - Product Description 26
  • Table 30: DIANA Biotechnologies Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 31: DIANA Assay - Insulin-like Growth Factor Receptor - Product Status 27
  • Table 32: DIANA Assay - Insulin-like Growth Factor Receptor - Product Description 27
  • Table 33: DiaSorin SpA Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 34: LIAISON - High Sclerostin Assay - Product Status 28
  • Table 35: LIAISON - High Sclerostin Assay - Product Description 29
  • Table 36: LIAISON - Hyperphosphate Low Bone Turnover Assay - Product Status 29
  • Table 37: LIAISON - Hyperphosphate Low Bone Turnover Assay - Product Description 29
  • Table 38: LIAISON XL - Sclerostin Assay - Product Status 30
  • Table 39: LIAISON XL - Sclerostin Assay - Product Description 30
  • Table 40: Immunodiagnostic Systems Holdings plc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 41: IDS-iSYS Cortisol Assay - Product Status 31
  • Table 42: IDS-iSYS Cortisol Assay - Product Description 31
  • Table 43: IDS-iSYS MGP Assay - Product Status 32
  • Table 44: IDS-iSYS MGP Assay - Product Description 32
  • Table 45: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 46: Rapid Diagnostic Test - Vitamin D - Product Status 33
  • Table 47: Rapid Diagnostic Test - Vitamin D - Product Description 33
  • Table 48: OJ-Bio Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 49: Parathyroid Hormone Assay - Product Status 35
  • Table 50: Parathyroid Hormone Assay - Product Description 35
  • Table 51: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 52: Cobas 6000 Analyzer Series With c 501 Module - IGF BP3 Assay - Product Status 36
  • Table 53: Cobas 6000 Analyzer Series With c 501 Module - IGF BP3 Assay - Product Description 37
  • Table 54: Cobas 6000 Analyzer Series With c 501 Module - IGF-1 Assay - Product Status 37
  • Table 55: Cobas 6000 Analyzer Series With c 501 Module - IGF-1 Assay - Product Description 37
  • Table 56: Cobas 8000 Analyzer Series With c 502 Module - IGF BP3 Assay - Product Status 37
  • Table 57: Cobas 8000 Analyzer Series With c 502 Module - IGF BP3 Assay - Product Description 38
  • Table 58: Cobas 8000 Analyzer Series With c 502 Module - IGF-1 Assay - Product Status 38
  • Table 59: Cobas 8000 Analyzer Series With c 502 Module - IGF-1 Assay - Product Description 38
  • Table 60: Cobas 8000 Analyzer Series With c 701 Module - IGF BP3 Assay - Product Status 40

List of Figures

  • Figure 1: Individual and Specified Hormones - Pipeline Products by Stage of Development 8
  • Figure 2: Individual and Specified Hormones - Pipeline Products by Segment 9
  • Figure 3: Individual and Specified Hormones - Pipeline Products by Territory 10
  • Figure 4: Individual and Specified Hormones - Pipeline Products by Regulatory Path 11
  • Figure 5: Individual and Specified Hormones - Pipeline Products by Estimated Approval Date 12
Back to Top